Business Overview: SS Innovations International, Inc. (NASDAQ: SSII)

---

Executive Summary

SS Innovations International is an India-based medical device company that designs, manufactures, and commercializes the SSi Mantra surgical robotic system, a multi-arm, multi-port platform used to perform minimally invasive surgery across cardiac, general, urology, gynecology, and other specialties. The company's strategy is to compete with entrenched Western incumbents (chiefly Intuitive Surgical's da Vinci platform) on price, offering a system priced at a fraction of a da Vinci, aimed at hospitals in India and other price-sensitive emerging markets that cannot justify the capital outlay of established systems.

SSII is in a hyper-growth, pre-profitability phase: full-year 2025 revenue reached $42.5 million, more than double the $20.6 million reported in 2024, driven by 103 new SSi Mantra installations during the year (bringing the cumulative installed base to 168 systems, the large majority in India) and a near-doubling of cumulative procedure volume to 7,885 surgeries. The company remains unprofitable, posting a $12.1 million net loss in 2025, though the loss narrowed from $19.2 million in 2024 as the installed base began generating recurring instrument, consumable, and service revenue alongside capital equipment sales.

---

1. Core Business Model & How They Work

SS Innovations generates revenue through a razor-and-blade model common to surgical robotics: it sells (or places) the capital robotic system, then earns recurring revenue from the proprietary instruments, drapes, and consumables used in every procedure, plus service and training contracts.

 Hospital/Surgical Center
          |
          v
 [Capital Sale/Placement] --> SSi Mantra System Install
          |
          v
 [Surgeon Training & Certification]
          |
          v
 [Per-Procedure Revenue] ➡️ Reusable/Disposable Instruments ➡️ Service Contracts
          |
          v
 Recurring Revenue Stream (Instruments + Service + Upgrades)

The company manufactures the system domestically in India, which keeps its bill-of-materials and labor costs well below a Western-built competitor, letting it price a full system well under the cost of an incumbent platform while still improving gross margins as instrument-attach rates climb with each new placement.

---

2. Business Segments

SS Innovations operates as a single integrated business — surgical robotics — rather than multiple reportable segments. Its activity nonetheless spans three functional pillars:

                SS Innovations International
                          |
    -----------------------------------------------
    |                     |                        |
Capital Equipment    Instruments &             Training &
(SSi Mantra          Consumables               Service
 system sales)        (per-procedure)           (surgeon certification,
                                                  maintenance contracts)

Capital Equipment is the highest-visibility revenue line and the primary growth driver, with 103 units placed in 2025 alone. Instruments & Consumables is the segment management is counting on to scale fastest as the installed base matures, since each of the 168 installed systems generates recurring per-case revenue indefinitely. Training & Service supports surgeon adoption — a critical bottleneck for any new robotic platform, since hospitals will not buy a system their surgeons cannot be credentialed to use.

---

3. Product Portfolio

---

4. Competitive Landscape

SS Innovations competes against far larger, better-capitalized incumbents in the global surgical robotics market:

• Intuitive Surgical (da Vinci) — the dominant global leader by a wide margin, with the largest installed base, longest clinical track record, and deepest surgeon-training ecosystem.
• Asensus Surgical — smaller U.S.-based competitor focused on digital laparoscopy and machine-vision-assisted systems.
• CMR Surgical (Versius) — UK-based competitor targeting modular, portable robotic systems for broader hospital adoption.
• Johnson & Johnson (Ottava, in development) and Medtronic (Hugo) — large medtech conglomerates investing heavily to enter the robotic-surgery space.
• Olympus and Shanghai Microport MedBot — additional entrants, with MedBot in particular targeting many of the same price-sensitive emerging markets (starting in China) that SSII is pursuing.

              High Price / Established Brand
                        |
         Intuitive Surgical (da Vinci)
                        |
    J&J (Ottava) •      |      • Medtronic (Hugo)
                        |
  Low Price -------------------- High Price
                        |
   SS Innovations •     |     • CMR Surgical (Versius)
   (SSi Mantra)         |
                        |
              Low Price / Emerging-Market Focus

SSII's positioning is deliberately at the low-price, emerging-market end: its principal competitive argument is not clinical superiority but affordability and local manufacturing economics that let hospitals in India and similar markets adopt robotic surgery for the first time.

---

5. Strategic Strengths & Risks

Strengths: SS Innovations has a genuine first-mover advantage in India's price-sensitive robotic surgery market, where da Vinci's cost structure has historically limited penetration. Its triple-digit installation growth (103 systems added in 2025 vs. 47 in 2024) and near doubling of annual procedure volume show real clinical traction, not just equipment sitting idle. Domestic manufacturing in India gives it a durable cost advantage over any import-dependent competitor targeting the same market.

Risks: The company is still burning cash — a $12.1 million net loss and $18.5 million of operating cash outflow in 2025 against only $3.2 million of unrestricted cash on hand at year-end — and depends heavily on financing from its principal shareholder (a $28.0 million convertible note during 2025) and a post-year-end $18.6 million private placement to fund 2026 growth. Clinical safety and long-term outcomes data for the Mantra platform are far thinner than for the two-decades-old da Vinci system, which could slow adoption outside India or invite regulatory scrutiny as the company seeks to expand geographically. Heavy reliance on the India market also concentrates the company's fortunes with that country's hospital capital-spending cycle and regulatory environment.

---

6. Financial Overview

---

7. Summary Conclusion

SS Innovations International is a high-growth, high-risk emerging-market surgical robotics story rather than a stable, cash-generative business. Its core asset — the SSi Mantra system — has found genuine commercial traction in India by undercutting the price of Intuitive Surgical's da Vinci on cost, and its installed base and procedure volumes are both compounding quickly. But the company remains dependent on external and related-party financing to cover ongoing losses, operates with a thin cash cushion, and faces both an entrenched global leader and a wave of well-funded new entrants (J&J, Medtronic, Shanghai Microport) all racing toward the same lower-cost end of the market SSII currently has mostly to itself.